BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

• Published in: Cancer Immunology, Immunotherapy Vol. 72; no. 7; pp. 2529 - 2539
• Main Authors: Sordo-Bahamonde, Christian, Lorenzo-Herrero, Seila, Martínez-Pérez, Alejandra, Gonzalez-Rodriguez, Ana P., Payer, Ángel R., González-García, Esther, Aguilar-García, Candelaria, González-Rodríguez, Sara, López-Soto, Alejandro, García-Torre, Alejandra, Gonzalez, Segundo
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2023; Springer Nature B.V
• Subjects: Antigens, CD19 - metabolism; Antitumor activity; Brief Report; BTLA protein; Cancer Research; CD19 antigen; CD3 antigen; CD4 antigen; CD4-Positive T-Lymphocytes; CD8 antigen; CD8-Positive T-Lymphocytes; Chronic lymphocytic leukemia; Humans; Immune checkpoint; Immunology; Immunosuppression; Interleukin 2; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - metabolism; Lymphocytes; Lymphocytes T; Medicine; Medicine & Public Health; Monoclonal antibodies; Oncology; Receptors, Immunologic - metabolism; γ-Interferon; BTLA; CLL; Checkpoint; HVEM; Leukemia; T cell

Patients with chronic lymphocytic leukemia (CLL) progressively develop marked immunosuppression, dampening innate and adaptive-driven antitumor responses. However, the underlying mechanisms promoting immune exhaustion are largely unknown. Herein, we provide new insights into the role of BTLA/HVEM ax...